Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(16 sites)

United States

University of Arizona, Tucson, Arizona

University of California, Los Angeles (UCLA), Los Angeles, California

University of California San Francisco, San Francisco, California

University of Colorado I Anschutz Medical Campus, Aurora, Colorado

Yale University, New Haven, Connecticut